1. Home
  2. SYNX vs APVO Comparison

SYNX vs APVO Comparison

Compare SYNX & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

HOLD

Current Price

$1.00

Market Cap

7.3M

Sector

N/A

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$4.17

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYNX
APVO
Founded
2005
2016
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
8.3M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
SYNX
APVO
Price
$1.00
$4.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.2M
48.9K
Earning Date
05-01-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.13
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
$32.35
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.25
52 Week High
$2.15
$13.11

Technical Indicators

Market Signals
Indicator
SYNX
APVO
Relative Strength Index (RSI) 43.40 35.48
Support Level $0.93 $3.95
Resistance Level $1.31 $7.65
Average True Range (ATR) 0.09 0.32
MACD -0.02 0.01
Stochastic Oscillator 21.27 30.26

Price Performance

Historical Comparison
SYNX
APVO

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: